The emergence of new drugs for overactive bladder

Bibliography

• ABRAMS P, CARDOZO L, FALL M et al.: The standardisation of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol. Urodyn. (2002) 21(2):167-178.
   PubMed Web of Science ®Google Scholar
• DMOCHOWSKI R, APPELL RA: Advancements in minimally invasive treatments for female stress urinary incontinence. Curr. Urol. Rep. (2003) 4(5):350-355.
   PubMedGoogle Scholar
• LAI HH, BOONE TB, APPELL RA: Pharmacologic treatment for detrusor overactivity. Curr. Urol. Rep. (2002) 3(5):365-372.
   PubMedGoogle Scholar
• ANDERSSON KE, HEDLUND P: Pharmacologic perspective on the physiology of the lower urinary tract. Urology (2002) 60:13-20.
   PubMedGoogle Scholar
• DE GROAT WC: The urothelium in overactive bladder: passive bystander or active participant? Urology (2004) 64:7-11.
   PubMed Web of Science ®Google Scholar
• STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol. (2003) 20(6):327-336.
   PubMed Web of Science ®Google Scholar
• MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THÜROFF J, WEIN AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. (2001) 87(9):760-766.
   PubMed Web of Science ®Google Scholar
• HU T, WAGNER TH, BENTKOVER JD, LEBLANC K, ZHOU SZ, HUNT T: Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology (2004) 63(3):461-465.
   PubMed Web of Science ®Google Scholar
• ROVNER ES: Trospium chloride in the management of overactive bladder. Drugs (2004) 64(21):2433-2446.
   PubMed Web of Science ®Google Scholar
• STEWART K, MCGHAN WF, OFFERDAHL T, COREY R: Overactive bladder patients and the role of the pharmacist. J. Am. Pharm. Assoc. (2002) 42(3):469-476.
   Google Scholar
• VAN DER VAART CH, DE LEEUW JRJ, ROOVERS JPWR, HEINTZ APM: The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int. (2002) 90:544-549.
   PubMed Web of Science ®Google Scholar
• USHIROYAMA T, IKEDA A, UEKI M: Prevalence, incidence, and awareness in the treatment of menopausal urinary incontinence. Maturitas (1999) 33(2):127-132.
   PubMed Web of Science ®Google Scholar
• SIMEONOVA Z, MILSOM I, KULLENDORFF AM, MOLANDER U, BENGTSSON C: The prevalence of urinary incontinence and its influence on the quality of life in women from an urban Swedish population. Acta Obstet. Gynecol. Scand. (1999) 78(6):546-551.
   PubMed Web of Science ®Google Scholar
• DOLAN LM, CASSON K, MCDONALD P, ASHE RG: Urinary incontinence in northern Ireland: a prevalence study. BJU Int. (1999) 83(7):760-766.
   PubMed Web of Science ®Google Scholar
• ROBERTS RO, JACOBSEN SJ, RHODES T et al.: Urinary incontinence in a community-based cohort: prevalence and healthcare-seeking. J. Am. Geriatr. Soc. (1998) 46(4):467-472.
   PubMed Web of Science ®Google Scholar
• APPELL RA, SAND P, DMOCHOWSKI R et al.: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartate in the treatment of overactive bladder: results of the OBJECT trial. Mayo Clin. Proc. (2001) 76(4):358-363.
   PubMed Web of Science ®Google Scholar
• DIOKNO AC, APPELL RA, SAND PK et al.: Prospective, randomized double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc. (2003) 78(6):687-695.
   PubMed Web of Science ®Google Scholar
• ZINNER N, GITTELMAN M, HARRIS R et al.: Trospium chloride improves overactive bladder symptoms: a multicenter Phase III trial. J. Urol. (2004) 171(6):2311-2315.
   PubMed Web of Science ®Google Scholar
• LAWRENCE M, GUAY, BENSON SR, ANDERSON MJ: Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy (2000) 20(4):470-475.
   PubMed Web of Science ®Google Scholar
• KELLEHER CJ, CARDOZO LD, KHULLAR V, SALVATORE S: A new questionnaire to assess the quality of life of urinary incontinent women. Br. J. Obstet. Gynaecol. (1997) 104(12):1374-1379.
   PubMedGoogle Scholar
• ECHOLS K, VERMA U, POLICARO F et al.: Idiopathic bladder hyperactivity and ditropan: an efficacy and compliance issue [abstract]. Obstet. Gynecol. (2000) 95(4 supp1):S24.
   Google Scholar
• APPELL RA, DIOKNO A, ANTOCI J et al.: One-year, prospective, open-label trial of controlled-release oxybutynin for overactive bladder in a community-based population [abstract]. Neurourol. Urodyn. (2002) 19:526.
   Google Scholar
• APPELL RA, ABRAMS P, DRUTZ HP, VAN KERREBROECK PE, MILLARD R, WEIN A: Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J. Urol. (2001) 19(2):141-147.
   PubMed Web of Science ®Google Scholar
• GUAY DRP: Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin. Phamocokinet. (2003) 42(14):1243-1285.
   PubMed Web of Science ®Google Scholar
• BIRNS J, LUKKARI E, MALONE-LEE JG et al.: A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int. (2000) 85:793-398.
   PubMed Web of Science ®Google Scholar
• VERSI E, APPELL RA, MOBLEY D et al.: Dry mouth with convencional and controlled-release oxybutynin in urinary incontinence. Obstet. Gynecol. (2000) 95(5):718-721.
   PubMed Web of Science ®Google Scholar
• BARKIN J, CORCOS J, RADOMSKI S et al.: A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin. Ther. (2004) 26(7):1026-1036.
   PubMed Web of Science ®Google Scholar
• ANDERSON RU, MOBLEY BB, SALTZSTEIN D et al.: Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J. Urol. (1999) 161:1809-1812.
   PubMed Web of Science ®Google Scholar
• DAVILA GW, DAUGHERTY CA, SANDERS SW et al.: A short-term multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J. Urol. (2001) 166:140-145.
   PubMed Web of Science ®Google Scholar
• DMOCHOWSKI RR, SAND PK, ZINNER NR et al.: Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology (2003) 62(2):237-242.
   PubMed Web of Science ®Google Scholar
• HARVEY MA, BAKER K, WELLS GA: Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am. J. Obstet. Gynecol. (2001) 185(1):56-61.
   PubMed Web of Science ®Google Scholar
• APPELL RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology (1997) 50(6A Suppl.):90-96.
   PubMed Web of Science ®Google Scholar
• KHULLAR V, HILL S, LAVAL KU, SCHOITZ HA, JONAS U, VERSI E: Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology (2004) 64(2):269-274.
   PubMed Web of Science ®Google Scholar
• VAN KERREBROECK P, KREDER K, JONAS U et al.: Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology (2001) 57(3):414-421.
   PubMed Web of Science ®Google Scholar
• HOMMA Y, PAICK JS, LEE JG et al.: Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. (2003) 92(7):741-747.
   PubMed Web of Science ®Google Scholar
• HÖFNER K, OELKE M, MACHTENS S, GRÜNEWALD V: Trospium chloride – an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J. Urol. (2001) 19:336-343.
   PubMed Web of Science ®Google Scholar
• TODOROVA A, VONDERHEIDE-GUTH B, DIMPFEL W: Effects of tolterodine, trospium chloride and oxybutynin on the central nervous system. J. Clin. Pharmacol. (2001) 41:636-644.
   PubMed Web of Science ®Google Scholar
• DIEFENBACH K, AROLD G, WOLLNY A, SCHWANTES U, HASELMANN J, ROOTS I: Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int. (2005) 95(3):346-349.
   PubMed Web of Science ®Google Scholar
• KERSHEN RT, HSIEH M: Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium and duloxetine. Curr. Urol. Rep. (2004) 5:1527-1537.
   Google Scholar
• CARDOZO L, CHAPPLE CR, TOOZS-HOBSON P et al.: Efficacy of trospium chloride in patients with detrusor instability: a placeto-controlled, randomized, double-blind, multicentre clinical trial. BJU Int. (2000) 85:659-664.
   PubMed Web of Science ®Google Scholar
• ALLOUSSI S, LAVAL KU, ECKERT R: Trospium chloride in patients with motor urge syndrome: a double-blind, randomized, multicenter, placebo-controlled study. J. Clin. Res. (1998) 1:439-451.
   Web of Science ®Google Scholar
• STOHRER M, BAUER P, GIANNETTI BM, RICHTER R, BURGDORFER H, MURTZ G: Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol. Int. (1991) 47(3):138-143.
   PubMedGoogle Scholar
• MADERSBACHER H, STOHRER M, RICHTER R, BURGDORFER H, HACHEN HJ, MURTZ: Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br. J. Urol. (1995) 75(4):452-456.
   PubMedGoogle Scholar
• HALASKA M, RALPH G, WIEDEMANN A et al.: Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J. Urol. (2003) 20:392-399.
   PubMed Web of Science ®Google Scholar
• HÖFNER K, HALASKA M, PRIMUS GL et al.: Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge syndrome: a double-blind, controlled, multicenter clinical trial [Abstract]. Neurourol. Urodyn. (2000) 19:487-488.
   Google Scholar
• SMULDER RA, KRAUWINKEL WJ, SWART PJ, HUANG M: Pharmacokinetics and safety of solefenacin succinate in healthy young men. J. Clin. Pharm. (2004) 44:1023-1033.
   PubMed Web of Science ®Google Scholar
• UCHIDA T, KRAUWINKEL WJ, MULDER H, SMULDERS RA: Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Br. J. Clin. Pharm. (2004) 58:4-7.
   PubMed Web of Science ®Google Scholar
• IKEDA K, KOBAYASHI S, SUZUKI M et al.: M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch. Pharm. (2002) 2:97-103.
   Google Scholar
• OKI T, SATO S, MIYATA K, YAMADA S: Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br. J. Pharm. (2005) 145:221-227.
   Google Scholar
• KOBAYASHI S, IKEDA K, MIYATA K: Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci. (2004) 74:843-853.
   PubMed Web of Science ®Google Scholar
• AMBUDKAR IS: Regulation of calcium in salivary gland secretion. Crit. Rev. Oral Biol. Med. (2000) 11:4-25.
   PubMedGoogle Scholar
• OHTAKE A, UKAI M, HATANAKA T et al.: In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol. (2004) 492:243-250.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, ARANO R, BOSCH JLHR et al.: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled Phase II dose-finding study. BJU Int. (2004) 93:71-77.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, RECHLBERGER T, AL-SHUKRI S et al.: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agen solifenacin in patients with symptomatic overactive bladder. BJU Int. (2004) 93:303-310.
   PubMed Web of Science ®Google Scholar
• CARDOZO L, LISEC M, MILLARD R et al.: Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol. (2004) 172:1919-1924.
   PubMed Web of Science ®Google Scholar
• HAAB F, CARDOZO L, CHAPPLE C, RIDDER AM: Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur. Urol. (2005) 47:376-384.
   PubMed Web of Science ®Google Scholar
• KELLEHER CJ, CARDOZO L, CHAPPLE CR, HAAB F, RIDDER AM: Improved quality of life in patients with overactive bladder symptoms treated with solefenacin. BJU Int. (2005) 95:81-85.
   PubMed Web of Science ®Google Scholar
• NAPIER C, GUPTA P: Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol. Urodyn. (2002) 21:A445.
   Google Scholar
• MIYAMAE K, YOSHIDA M, MURAKAMI S et al.: Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology (2003) 69:205-211.
   PubMed Web of Science ®Google Scholar
• KERBUSCH T, MILLIGAN PA, KARLSSON MO: Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br. J. Clin. Pharm. (2003) 57:170-180.
   Web of Science ®Google Scholar
• HAAB F, STEWART L, DWYER P: Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. (2004) 45:420-429
   PubMed Web of Science ®Google Scholar
• STEERS W, CORCOS J, FOOTE J, KRALIDAS G: An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. (2005) 95:580-586.
   PubMed Web of Science ®Google Scholar
• CHAPPLE C, STEERS W, NORTON P et al.: A pooled analysis of three Phase III studies to investiage the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. (2005) 95:993-1001.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, KOLODNER K, WESNES K: Assessment of cognitive function of the elderly population: effects of darifenacin. J. Urol. (2005) 173:493-498.
   PubMed Web of Science ®Google Scholar
• CARDOZO L, DIXON A: Increased warning time with darifenacin: a new concept in the management of urinary urgency. J. Urol. (2005) 173:1214-1218.
   PubMed Web of Science ®Google Scholar
• KIM YT, KWON DD, KIM J et al.: Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int. Braz. J. Urol. (2004) 30:275-278.
   PubMedGoogle Scholar
• DE GROAT WC: Influence of central serotonergic mechanisms on lower urinary tract function. Urology (2002) 59(Suppl. 5A):30-36.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, PEHRSON R: CNS involvement in overactive bladder. Drugs (2003) 63:2595-2611.
   PubMed Web of Science ®Google Scholar
• FOWLER C: Bladder afferents and their role in the overactive bladder. Urology (2002) 59(Supp 5A):37-42.
   PubMed Web of Science ®Google Scholar
• FRY CH, IKEDA Y, HARVEY R et al.: Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology (2004) 63(Supp 3A):24-31.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M, MIYAMAE K, IWASHITA H et al.: Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology (2004) 63(Supp 3A):17-23.
   PubMed Web of Science ®Google Scholar
• KIM Y, YOSHIMURA N, MASUDA H et al.: Antimuscarinc agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology (2005) 65:238-242.
   PubMed Web of Science ®Google Scholar